NASDAQ:CNAT - Conatus Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
$2.79 -0.10 (-3.46 %)
(As of 03/19/2019 10:36 AM ET)
Previous Close$2.89
Today's Range$2.76 - $2.97
52-Week Range$1.15 - $6.74
Volume4,245 shs
Average Volume941,603 shs
Market Capitalization$84.43 million
P/E Ratio-4.69
Dividend YieldN/A
Beta3.36

Headlines

Conatus Pharmaceuticals (NASDAQ CNAT) News Headlines

Source:
DateHeadline
Conatus up 22% ahead of Emricasan data presentationConatus up 22% ahead of Emricasan data presentation
seekingalpha.com - March 13 at 4:55 PM
Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal HypertensionConatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
finance.yahoo.com - March 13 at 10:01 AM
Analysts Set Expectations for Conatus Pharmaceuticals Incs Q2 2019 Earnings (CNAT)Analysts Set Expectations for Conatus Pharmaceuticals Inc's Q2 2019 Earnings (CNAT)
www.americanbankingnews.com - March 12 at 5:56 AM
Conatus (CNAT) Q4 Earnings Top Estimates, Emricasan in FocusConatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus
www.zacks.com - March 11 at 4:51 PM
Conatus Pharmaceuticals (CNAT) Price Target Cut to $8.00 by Analysts at HC WainwrightConatus Pharmaceuticals (CNAT) Price Target Cut to $8.00 by Analysts at HC Wainwright
www.americanbankingnews.com - March 11 at 11:29 AM
Conatus Pharmaceuticals Inc (CNAT) Receives Average Recommendation of "Hold" from BrokeragesConatus Pharmaceuticals Inc (CNAT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 10 at 10:49 AM
Conatus Pharmaceuticals (CNAT) Issues  Earnings ResultsConatus Pharmaceuticals (CNAT) Issues Earnings Results
www.americanbankingnews.com - March 9 at 2:21 PM
Conatus Pharmaceuticals (CNAT) CEO Steve Mento on Q4 2018 Results - Earnings Call TranscriptConatus Pharmaceuticals (CNAT) CEO Steve Mento on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 9 at 10:34 AM
Edited Transcript of CNAT earnings conference call or presentation 8-Mar-19 9:30pm GMTEdited Transcript of CNAT earnings conference call or presentation 8-Mar-19 9:30pm GMT
finance.yahoo.com - March 9 at 10:34 AM
Conatus Pharmaceuticals Reports 2018 Financial Results and Program UpdatesConatus Pharmaceuticals Reports 2018 Financial Results and Program Updates
finance.yahoo.com - March 8 at 5:10 PM
Conatus Pharmaceuticals (CNAT) to Release Earnings on FridayConatus Pharmaceuticals (CNAT) to Release Earnings on Friday
www.americanbankingnews.com - March 4 at 10:43 AM
Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial ResultsConatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results
finance.yahoo.com - March 1 at 11:22 AM
$8.63 Million in Sales Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter$8.63 Million in Sales Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter
www.americanbankingnews.com - March 1 at 4:58 AM
Biotechnology Companies Ramp up Funding as Deadly Diseases Come Into the Spotlight - PRNewswireBiotechnology Companies Ramp up Funding as Deadly Diseases Come Into the Spotlight - PRNewswire
www.prnewswire.com - February 27 at 4:57 PM
 Analysts Expect Conatus Pharmaceuticals Inc (CNAT) to Announce -$0.14 Earnings Per Share Analysts Expect Conatus Pharmaceuticals Inc (CNAT) to Announce -$0.14 Earnings Per Share
www.americanbankingnews.com - February 27 at 1:17 PM
Biotechnology Companies Ramp up Funding as Deadly Diseases Come Into the SpotlightBiotechnology Companies Ramp up Funding as Deadly Diseases Come Into the Spotlight
www.marketwatch.com - February 27 at 10:51 AM
Is Conatus Pharmaceuticals Inc.’s (NASDAQ:CNAT) CEO Pay Justified?Is Conatus Pharmaceuticals Inc.’s (NASDAQ:CNAT) CEO Pay Justified?
finance.yahoo.com - February 25 at 4:59 PM
Conatus And Emricasan In NASH Cirrhotic Portal Hypertension: The UpdateConatus And Emricasan In NASH Cirrhotic Portal Hypertension: The Update
seekingalpha.com - February 15 at 10:54 AM
Conatus (CNAT) Completes Enrollment in Phase II NASH StudyConatus (CNAT) Completes Enrollment in Phase II NASH Study
finance.yahoo.com - February 13 at 4:52 PM
Conatus completes enrollment in mid-stage study of emricasan in NASH cirrhosisConatus completes enrollment in mid-stage study of emricasan in NASH cirrhosis
seekingalpha.com - February 12 at 4:40 PM
Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis - GlobeNewswireConatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis - GlobeNewswire
globenewswire.com - February 12 at 10:55 AM
Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH CirrhosisConatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
finance.yahoo.com - February 12 at 10:55 AM
Todays Research Reports on Trending Tickers: Voyager Therapeutics and Conatus PharmaceuticalsToday's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals
finance.yahoo.com - January 30 at 10:12 AM
Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?
finance.yahoo.com - January 29 at 4:45 PM
Conatus up 6% premarket on publication of emricasan dataConatus up 6% premarket on publication of emricasan data
seekingalpha.com - January 28 at 10:32 AM
Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical TrialsConatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials
finance.yahoo.com - January 28 at 10:32 AM
Conatus Is Gearing Up For A Compelling 2019 With Multiple CatalystsConatus Is Gearing Up For A Compelling 2019 With Multiple Catalysts
seekingalpha.com - January 15 at 4:48 PM
Merck Doesnt Want To Be Left Out Of The NASH Race Either, Uses Option AgreementMerck Doesn't Want To Be Left Out Of The NASH Race Either, Uses Option Agreement
seekingalpha.com - January 5 at 9:22 AM
3 Reasons Biotech Should Rally In 20193 Reasons Biotech Should Rally In 2019
seekingalpha.com - January 4 at 8:10 AM
Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan - NasdaqConatus (CNAT) Focuses on Developing NASH Candidate Emricasan - Nasdaq
www.nasdaq.com - December 30 at 9:01 AM
Conatus (CNAT) Focuses on Developing NASH Candidate EmricasanConatus (CNAT) Focuses on Developing NASH Candidate Emricasan
www.zacks.com - December 28 at 4:47 PM
Gilead Doubles Down On Its NASH Pipeline With $1.5B DealGilead Doubles Down On Its NASH Pipeline With $1.5B Deal
seekingalpha.com - December 26 at 4:49 PM
A Closer Look At Conatus Pharmaceuticals Failed Clinical StudyA Closer Look At Conatus Pharmaceuticals' 'Failed' Clinical Study
seekingalpha.com - December 18 at 4:44 PM
Conatus: A Rare Investment For Opportunistic InvestorsConatus: A Rare Investment For Opportunistic Investors
seekingalpha.com - December 11 at 4:46 PM
Conatus: Was That Trial A Total Failure?Conatus: Was That Trial A Total Failure?
seekingalpha.com - December 11 at 4:46 PM
Conatus And Emricasan In NASH Cirrhotic Portal Hypertension: The Overlooked Therapeutic PromiseConatus And Emricasan In NASH Cirrhotic Portal Hypertension: The Overlooked Therapeutic Promise
seekingalpha.com - December 10 at 9:52 AM
Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint - MarketWatchShares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint - MarketWatch
www.marketwatch.com - December 8 at 9:16 AM
Why Conatus Pharma Shares Were HalvedWhy Conatus Pharma Shares Were Halved
247wallst.com - December 7 at 9:08 AM
Conatus Pharmaceuticals (CNAT) PT Lowered to $10 at OppenheimerConatus Pharmaceuticals (CNAT) PT Lowered to $10 at Oppenheimer
www.streetinsider.com - December 7 at 9:08 AM
Conatus Emricasan Misses Primary Endpoint in Mid-Stage StudyConatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
finance.yahoo.com - December 7 at 9:08 AM
Implied Volatility Surging for Conatus (CNAT) Stock OptionsImplied Volatility Surging for Conatus (CNAT) Stock Options
www.zacks.com - December 7 at 9:08 AM
Conatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. WainwrightConatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. Wainwright
www.streetinsider.com - December 7 at 9:08 AM
Conatus May Still Have A Path Forward After Latest Phase 2b DataConatus May Still Have A Path Forward After Latest Phase 2b Data
seekingalpha.com - December 7 at 9:08 AM
U.S. STOCKS ON THE MOVE-Chipmakers, oil stocks, Facebook, industrial stocks - NasdaqU.S. STOCKS ON THE MOVE-Chipmakers, oil stocks, Facebook, industrial stocks - Nasdaq
www.nasdaq.com - December 6 at 4:45 PM
Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis - GlobeNewswireConatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis - GlobeNewswire
globenewswire.com - December 6 at 4:45 PM
U.S. STOCKS ON THE MOVE-Apple, chipmakers, oil stocks, Boeing, Amazon, Conatus - NasdaqU.S. STOCKS ON THE MOVE-Apple, chipmakers, oil stocks, Boeing, Amazon, Conatus - Nasdaq
www.nasdaq.com - December 6 at 4:45 PM
U.S. STOCKS ON THE MOVE-Oil stocks, Facebook, Marvell Technology, Conatus Pharma - NasdaqU.S. STOCKS ON THE MOVE-Oil stocks, Facebook, Marvell Technology, Conatus Pharma - Nasdaq
www.nasdaq.com - December 6 at 4:45 PM
Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpointShares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint
finance.yahoo.com - December 6 at 4:45 PM
Conatus Pharmas emricasan flunks mid-stage NASH study; shares down 62% premarketConatus Pharma's emricasan flunks mid-stage NASH study; shares down 62% premarket
seekingalpha.com - December 6 at 9:08 AM
Conatus (CNAT) ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis Did Dot Meet Primary EndpointConatus (CNAT) ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis Did Dot Meet Primary Endpoint
www.streetinsider.com - December 6 at 9:08 AM
This page was last updated on 3/19/2019 by MarketBeat.com Staff

Featured Article: Discount Rate

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel